ESHAP regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:ESHAP Regimen; Etoposide-Solumedrol-High Dose Ara-C, Platinol Regimen
Overview
Overview
ESHAP regimen refers to a regimen consisting of etoposide, methylprednisolone (Solumedrol), high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin’s and Non-Hodgkin’s lymphoma[1][2] and rituximab added for the treatment of Diffuse large B-cell lymphoma. [3]
Regimen
Regimen
EEtoposide
SMethylprednisolone (Solumedrol)
HHigh-dose
ACytarabine (Ara-c)
PCisplatin (Platinol)
References
References
- ↑ 1.0 1.1 Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA; et al. (1994). “ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study”. J Clin Oncol. 12 (6): 1169–76. PMID 8201379.
- ↑ “NCI Thesaurus”.
- ↑ Montoro J, Andreola G, Gardellini A, Babic A, Negri M, Frungillo N; et al. (2014). “R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma”. Transfus Apher Sci. 50 (3): 411–4. doi:10.1016/j.transci.2014.03.006. PMID 24751603.
- ↑ “NCI Thesaurus”.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH